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During our life, we are surrounded by continuous threats from a diverse range of invading
pathogens. Our immune system has evolved multiple mechanisms to efficiently deal with
these threats so as to prevent them from causing disease.Terminal differentiation of mature
B cells into plasma cells (PC) – the antibody (Ab) secreting cells of the immune system – is
critical for the generation of protective and long-lived humoral immune responses. Indeed,
efficient production of antigen (Ag)-specific Ab by activated B cells underlies the success
of most currently available vaccines. The mature B-cell pool is composed of several sub-
sets, distinguished from one according to size, surface marker expression, location, and
Ag exposure, and they all have the capacity to differentiate into PCs. For a B-cell to acquire
the capacity to produce Abs, it must undergo an extensive differentiation process driven by
changes in gene expression.Two broad categories of Ags exist that cause B-cell activation
and differentiation:T cell dependent (TD) orT cell independent (TI). In addition to the B-cell
subset and nature of the Ag, it is important to consider the cytokine environment that can
also influence how B-cell differentiation is achieved.Thus, while many cytokines can induce
Ab-secretion by B cells after activation with mimics of TD and TI stimuli in vitro, they can
have different efficacies and specificities, and can often preferentially induce production of
one particular Ig isotype over another. Here, we will provide an overview of in vitro studies
(mouse and human origin) that evaluated the role of different cytokines in inducing the dif-
ferentiation of distinct B-cell subsets to the PC lineage. We will place particular emphasis
on IL-21, which has emerged as the most potent inducer of terminal B-cell differentiation
in humans. We will also focus on the role of IL-21 and defects in B-cell function and how
these contribute to human immunopathologies such as primary immunodeficiencies and
B-cell mediated autoimmune conditions.
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INTRODUCTION
The humoral arm of the immune system is critical for provid-
ing protective antibodies (Abs) against infection pathogens. The
Ab pool is maintained by long-lived plasma cells (PCs), which
continuously secrete Abs following their formation in response to
exposure to specific antigen (Ag). In 1948, Fagraeus was the first to
report that PCs are the outcome of terminal B-cell differentiation
and demonstrated their importance to Ab production in vitro (1).
We now know that B cells are capable of secreting multiple Ig iso-
types (IgM, IgG, IgA, IgE) and subclasses of these isotypes (IgG1–4,
IgA1–2) following the receipt of appropriate stimulate. However,
today – 65 years later – our understanding of the complexities of
PC development remains incomplete.
PLASMA CELL FORMATION: THE IMPORTANCE OF T CELLS,
CYTOKINES, AND TRANSCRIPTION FACTORS
Plasma cells are generated as a result of cognate interactions
between Ag-specific B cells, CD4+ T helper cells, and dendritic cells
in response to foreign Ags (Figure 1). These interactions can drive
B cells to become low-affinity short-lived, predominantly IgM-
secreting, plasmablasts that provide an initial wave of protection
against invading pathogens. More importantly though, they also
lead to the formation of germinal centers (GCs), which are spe-
cialized structures in the follicles of secondary lymphoid tissues
where somatic hypermutation (SHM) of immunoglobulin (Ig)
variable region genes and selection of high-affinity B cells occurs.
These selected high-affinity variants can then differentiate into
long-lived memory B cells or PCs (2, 3) (Figure 1). This differen-
tiation event is in part mediated by T follicular helper (Tfh) cells, a
distinct subset of CD4+ T cells characterized by expression of the
transcriptional repressor B-cell lymphoma-6 (Bcl-6), the surface
markers CXCR5, PD-1, ICOS, and CD40 ligand (CD40L), and pro-
duction of various cytokines including interleukin-4 (IL-4), IL-10,
and IL-21. Tfh cells localize to follicles and GCs – where they are
termed “GC Tfh cells” – where they can interact with B cells and
instruct their maturation into memory cells or PCs (4–6).
The differentiation of activated B cells into PC is regulated
by transcriptional programs and networks that are influenced by
numerous inputs and microenvironmental factors. These include
the nature of the Ag and of the responding B-cell subset, the
location in which Ag encounter occurs, and the accessory cells
involved (7, 8). The key transcription factors involved in regulating
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FIGURE 1 |T cell dependent B-cell differentiation. Following the receipt of
signals provided by the microenvironment [e.g., Ag, CD4+ T (Tfh) cells, DC],
naïve B cells undergo activation and can initially differentiate into either
extrafollicular short-lived Ab-secreting plasma cells (secreting predominantly
IgM), or can seed a germinal center (GC). Within GCs, B cells undergo
somatic hypermutation of their Ig V region genes and only those B cells with
the highest affinity are selected to then differentiate into long-lived memory B
cells or plasma cells that are capable of secreting a variety of Ig isotypes,
including the switched isotypes IgG, IgA, and IgE. The outcome of the GC
reaction is heavily influenced by Tfh cells, especially those within the GC
itself. These cells are not depicted on the figure but they contribute greatly at
this stage of B-cell differentiation. Following re-encounter with the initiating
Ag, memory B cells rapidly differentiate into plasma cells. The differentiation
of naïve B cells to these distinct effector fates is controlled by the balanced
expression and regulated function of various transcription factors, including
(but not exclusively) PAX5, BCL-6, BLIMP-1, XBP-1, and IRF4.
PC formation include the transcriptional repressors Bcl-6 and B-
lymphocyte induced maturation protein (BLIMP)-1, encoded by
the PRDM1 gene, as well as transcription factors PAX5, X-box-
binding protein-1 (XBP-1), and IFN-induced regulatory factor 4
(IRF4) (Figure 1) (7, 8). Thus, while Bcl-6 is expressed in GC
B cells and is required for the GC formation (9–11), it blocks
PC differentiation and maintains a GC B-cell fate by suppressing
expression of BLIMP-1, which is considered the master regulator
of PC differentiation, being required for – or at least correlated
with – PC commitment in mice and humans (Figure 1) (12–15).
BLIMP-1 expression controls PC differentiation by restraining the
mature B-cell gene expression program by down-regulating a set
of genes including MHC, CIITA, PAX5, and CMYC, which result
in a decrease of MHC class II expression, loss of B-cell identity,
and cessation of proliferation, respectively (8, 14). BLIMP-1 may
also co-ordinate expression of XBP 1, which allows expansion of
the secretory apparatus necessary for high-level protein synthesis
in PC differentiation (Figure 1) (16).
Cytokines represent a diverse group of small soluble proteins
that can function as growth and differentiation factors in autocrine
or paracrine ways. Cytokines exhibit considerable redundancy, in
that many cytokines share similar functions. Through binding
to specific cell surface receptors, they initiate signal transduc-
tion pathways that are critical for a diverse spectrum of functions,
including induction of immune responses, cell proliferation, dif-
ferentiation, and apoptosis. The key contribution of cytokines to
B-cell differentiation lies in their ability to modulate expression
of these transcription factors such that they regulate Ig secre-
tion by B cells activated with mimics of T cell dependent (TD)
(e.g., CD40L) or T cell independent (TI) [e.g., engaging the B-cell
receptor (BCR), Toll-like receptors (TLRs)] stimuli in vitro and,
by extension, in vivo. The effects of cytokines on B-cell differentia-
tion is evidenced not only by the magnitude of the Ab response but
also the quality, in terms of the particular Ig isotype(s) induced.
Although many cytokines are capable of promoting B-cell differ-
entiation, the relative roles of specific factors, and the hierarchy
of the interactions between several cytokines, has only emerged in
the last 10 years.
DISCOVERY OF T CELL-DERIVED FACTORS AS CRITICAL
MEDIATORS OF B-CELL DIFFERENTIATION AND PC
GENERATION
The concept that cross-linking of the BCR initiates B-cell activa-
tion and facilitates these cells to respond to T-cell-derived soluble
factors and undergo proliferation and differentiation to become
Ab-secreting cells was first appreciated in the 1970s (17–20). The
different factors were classically grouped as T cell-replacing fac-
tors, some of which influence the replication of B cells (B-cell
growth factor), while others directly cause B-cell differentiation
to Ab-secretion cells (B-cell differentiation factor) (21). While it
gradually emerged that these T cell-derived factors are Ag non-
specific, genetically non-restricted, and are indeed involved in the
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differentiation of B cells into Ab-secreting cells, at this time no sin-
gle factor had been isolated or molecularly cloned, and it remained
unknown how many factors were actually involved in, or required
for, B-cell terminal differentiation (22, 23).
The molecular revolution of the 1980s saw the cloning and
characterization of several cytokines – IL-2, IL-4, IL-5, IL-6, IFNs –
which had B-cell growth and differentiation capacity (Table 1).
This continued into the 1990s with the discovery of IL-10, IL-12,
IL-13, IL-15, TNFα, BAFF, and APRIL, which could promote var-
ious aspects of B-cell function (Figure 2; Table 1). Thus, these
cytokines enhanced proliferation and induced isotype switch-
ing, PC formation, and Ig secretion by activated B cells (22–47)
(Table 1; Figure 2). Importantly, this era also saw the identifica-
tion of CD40L – transiently expressed on the surface of activated
CD4+ T cells – which, together with these cytokines, was revealed
to be a critical regulator of many facets of B-cell biology (48).
Specifically, while CD40L (or anti-CD40 mAb) itself had minimal
effect on Ab-secretion by murine and human B cells, Ab-secretion
could be induced in an isotype specific manner in the presence
of exogenous cytokines (Figure 2; Table 1). Thus, IL-4 and IL-13
directs naïve human B cells to switch to IgG4 and IgE expression
and production, while IL-4 exerts a similar effect for inducing IgG1
and IgE by murine B cells (Table 1), with IL-5 acting synergistically
with IL-4 in these murine B-cell responses (25, 28, 29, 41, 49–51).
The significance of these in vitro findings was underscored by the
generation of IL-4 deficient mice, which had significantly reduced
production of IgE following nematode infection (52). Interest-
ingly, IL-4-induced IgE production by human B cells could be
enhanced by IL-6 or TNFα (33, 45), or inhibited by IL-8 (53), IL-
12 (54), or IFN-α or IFN-γ (33, 40). While murine B cells were
initially reported to be unresponsive to IL-13 (55), subsequent
studies noted that IL-13 could enhance Ab production by murine
B cells in vivo and that it acts directly on B cells in vitro to increase
survival, thereby increasing Ab production (56). Additional sup-
port for a role for IL-13 in modulating murine B cells came from
the analysis of IL-13 transgenic mice, which exhibited substan-
tially increased levels of serum IgE, even in the absence of IL-4
(57). Similarly, while deficiency of either IL-4 or IL-13 reduced
the levels of Ag-specific IgE, combined deficiency of both IL-4
and IL-13 resulted in undetectable levels of IgE (58). Thus, it is
likely that IL-4 and IL-13 co-operate in both mice and humans
to regulate Ig class switching, especially to IgE. IL-10 also strongly
modulated the behavior of human B cells, significantly increas-
ing the levels of IgM, IgG1, and IgA secreted by human B cells
stimulated through CD40 or the BCR (42). IL-10 was also found
to induce class switching in human naïve B cells to IgG1 and
IgG3 (59), and together with TGF-β promoted switching to IgA
(31). IL-10 also mediated the differentiation of GC and memory
B cells to PCs (Table 1) (26). The ability of IL-4, IL-10, and IL-13
to induce isotype switching reflected their abilities to upregulate
expression of activation induced cytidine deaminase (AICDA), an
enzyme critical for class switch recombination, while IL-10 medi-
ated PC generation by inducing BLIMP-1 (7, 8, 60). The effects
of IL-10, however, appear to be species specific because serum Ig
levels were unaffected in mice that were either deficient for IL-
10 or that expressed IL-10 from a transgene (61, 62). Similar to
CD40L, the membrane bound form of TNF-α was also found to
be transiently expressed on human activated CD4+ T cells, and
could co-stimulate polyclonal Ig secretion induced in human B
cells co-cultured with mitogen-stimulated CD4+ T cells, or their
membranes, together with IL-4 (27, 63) (Table 1).
IL-2 has had a long history of being documented of enhancing
Ig secretion by activated human B cells (Table 1) (38, 39). Consis-
tent with the structural and functional similarities between IL-2
and IL-15, it was not surprising that IL-15 could also stimulate
proliferation and induce secretion of IgM, IgG1, and IgA, but not
IgG4 or IgE, by CD40L-primed B cells. This activity of IL-15 was
comparable to that of IL-2 (24).
More recently, the TNF-related molecule BAFF,and its homolog
APRIL, has emerged as a global regulator of B-cell development
and function (64–66). While a primary role for BAFF lies in the
ability to promote the survival of B cells at the transitional stage of
development (65), both BAFF and APRIL can also induce the mol-
ecular events associated with isotype switching to IgG and IgA, and
to IgE in the presence of IL-4. Furthermore, the secretion of these
Ig isotypes occurred when the B cells also received signals through
the BCR (64, 66). BAFF and APRIL can also sustain the survival
of PCs in vivo and in vitro (66, 67). BAFF functions by binding
to the surface receptors BAFF-R, TACI, or BCMA; APRIL can also
activate B cells by binding to TACI and BCMA (65, 66) (Table 1).
Interestingly, these effects of BAFF and APRIL appear to be medi-
ated through different receptors. Thus, the pro-survival effects of
BAFF on transitional and naïve B cells are delivered through BAFF-
R, while this effect on PCs occurs predominantly through BCMA.
On the other hand, BAFF-R and TACI mediates isotype switching
to IgG, IgA, and IgE induced by BAFF and APRIL, respectively (64–
66). Lastly, heparan sulfate proteoglycans can also act as a receptor
for APRIL, and this appears to be important for mediating the
pro-survival effects of APRIL on BM PCs (67–69).
Collectively, it is clear that myriad cytokines and combinations
thereof, are capable of eliciting activation and terminal differen-
tiation of human B cells to differing extents. However, with the
discover of IL-21 in 2001, and the subsequent characterization
of its function on human and murine B cells during the fol-
lowing decade, the physiological significance of many of these
factors in initiating humoral immune responses needs to be re-
addressed as IL-21 has emerged as the most potent inducer of B
cell differentiation.
PLEIOTROPIC EFFECTS OF IL-21 ON HUMAN AND MURINE
B-CELL DIFFERENTIATION
IL-21 belongs to the type I family of cytokines that also includes
IL-2, IL-4, IL-7, IL-9, and IL-15, all of which bind to and form a
complex with the commonγ-chain (γc) and their private receptors
(70–73). The IL-21 receptor (IL-21R) is expressed by fibroblasts,
keratinocytes, and intestinal epithelial cells, but more importantly
is also expressed on lymphocytes (T, B, NK cells), macrophages,
and dendritic cells, and the levels of expression can be increased
following cellular activation (70, 71, 74–77). IL-21 is predomi-
nantly produced by activated CD4+ T cells and NKT cells (78–80),
with the greatest production being by Tfh and GC Tfh cells (4–
6). Akin to most cytokines, IL-21 exerts its effect by activating
Janus kinase/signal transducers and activators of transcription
(JAK/STAT) signaling pathways, specifically Jak1 and Jak3, and
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Table 1 | Contribution of different cytokines to the in vitro behavior of human B cells.
Cytokine Effect on B cells Reference
CD40L Induces activation, blastogenesis, proliferation (25)
IL-2 Enhances proliferation of CD40L-stimulated B cells (25, 26, 30, 36, 38, 39,
44, 104, 144, 145)Co-operates with other cytokines/stimulatory factors to enhance differentiation of activated B cells
IL-4 Enhances proliferation induced by CD40L, BCR engagement (25, 33, 37, 40, 45)
Induces expression of AICDA
Induces CSR, preferentially to IgG1, IgG4, and IgE
IL-6 Promotes survival and function of in vitro-derived as well as primary and malignant plasma cells (32, 44–47)
IL-10 Enhances proliferation induced by CD40L, BCR engagement (25, 26, 31, 34, 42, 59,
60, 144)Induces expression of AICDA, BLIMP-1
Induces CSR, preferentially to IgG1, IgG3
Co-operates with TGF-β to induce CSR to IgA
Promotes differentiation of B cells to become plasma cells secreting IgM, IgG, IgA
IL-12 Induces B cells to differentiate into IgM-secreting cells (32, 54)
Co-operates with IL-6 to augment IgM secretion
Suppresses IL-4-induced IgE production
IL-13 Enhances proliferation induced by CD40L, BCR engagement (28, 29, 41, 50)
Induces expression of AICDA
Induces CSR, preferentially to IgG1, IgG4, and IgE
Effects essentially overlap with those of IL-4
IL-15 Enhances proliferation of B cells stimulated with CD40L or BCR engagement (24)
Induces secretion of IgM, IgG1, and IgA by CD40L-stimulated B cells
Magnitude of the effect was comparable to IL-2
IL-21 Currently, the most potent cytokine identified capable of regulating human B-cell function (60, 71, 76, 83, 84,
96–101, 103, 106, 107,
121)
Enhances proliferation induced by CD40L, BCR engagement
Induces expression of AICDA, BCL-6, BLIMP-1, XBP-1
Induces CSR, preferentially to IgG1, IgG3, and IgA1
Promotes differentiation of B cells to become plasma cells secreting IgM, IgG, IgA, and IgE
Synergizes with IL-4 for CSR to IgG and secretion of IgE
Sustain survival of primary plasma cells present in secondary lymphoid organs
Growth and survival factor for malignant plasma cells (i.e., myeloma)
Requires functional STAT3 to induce plasma cells differentiation
IFNα, IFNγ Inhibits CD40L-induced B-cell proliferation (25, 33, 36, 40)
Inhibits IL-4 induced IgE secretion
IFNα primes activated B cells to differentiate into precursors of plasmablasts, that become plasmablasts
in response to IL-6
TNFα Membrane TNFα expressed by CD4+T cells acts as a co-stimulus to promote B-cell differentiation
induced by CD40L and IL-4
(27, 33, 63)
BAFF/APRIL BAFF promotes survival of transitional B cells, as well as of early plasma cells and some malignant
plasma cells
(64–66)
BAFF and TACI can induce CSR to various isotypes, and can induce secretion of these Ig’s when
combined with BCR signaling and cytokines (e.g., IL-4, IL-10, IL-15)
TGFβ Inhibits IL-4 induced IgE secretion (31, 33)
Can induce CSR to IgA, in combination with IL-10
CSR, class switch recombination.
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FIGURE 2 | Cytokine-induced differentiation of human B cells in vitro:
requirement for IL-21 signaling in vivo. In vitro studies demonstrated that
human B cells could undergo events such as Ig class switching and
differentiation to become Ig-secreting cells following stimulation with a
diverse range of cytokines. However, analysis of individuals with hypomorphic
mutations in genes encoding STAT3, γc (IL2RG), JAK3, or IL-21R have
revealed that this pathway – activated by IL-21 – is critical for the generation of
memory B cells and the establishment of Ag-specific Abs in vivo. Thus,
although cytokines such as IL-4, IL-13, IL-10, and BAFF/APRIL are strong B-cell
growth and differentiation factors, their function is insufficient to compensate
for impaired IL-21/IL-21R signaling in vivo in the setting of generating robust,
long-lived Ag-specific Ab, and memory responses. Consequently,
IL-21-mediated B-cell activation is a necessary and sufficient step in the
generation of protective long-lived humoral immune responses in humans.
STAT1, STAT3, and to a lesser extent STAT5 (72, 81–84). The
initial description of IL-21 hinted at its B-cell tropism, inas-
much that Parrish-Novak et al. showed that IL-21 significantly
co-stimulated proliferation of human blood B cells induced by
anti-CD40 mAbs (71). Since then, several studies have confirmed
that IL-21 is an important regulator of B-cell activation, prolif-
eration, PC differentiation, and Ab-secretion in both mice and
humans.
THE ROLE OF IL-21 IN MURINE ACTIVATED B-CELL PROLIFERATION,
APOPTOSIS, PC DIFFERENTIATION, Ab-SECRETION, AND MEMORY
B-CELL FORMATION
In a seminal study, Ozaki et al. demonstrated that the IL-21 signal-
ing pathway is involved in regulating Ab production and isotype
switching (85). They showed that IL-21R−/− mice, despite hav-
ing normal lymphoid development, have significantly diminished
total serum and Ag-specific IgG1 titers but elevated IgE levels in
response to TD Ag immunization compared to wild-type ani-
mals. Ag-specific IgG2b and IgG3 serum levels were also decreased
whereas IgG2a and IgM titers were largely unaffected in the absence
of the IL-21R. The decreased IgG1 response appeared to result
from a reduction in the generation of Ag-specific IgG1 produc-
ing PCs. These in vivo data established that IL-21 has a critical
role in inducing IgG1 production, while concomitantly suppress-
ing IgE responses. Strikingly, IL-4−/−IL-21R−/− double-knockout
mice displayed a more severe phenotype, characterized by a more
dramatically reduced IgG response. Furthermore, the strong up-
regulation of IgE secretion in IL-21R−/− mice was abrogated in
IL-4−/−IL-21R−/− mice indicating that the “hyper-IgE” pheno-
type of IL-21R−/− mice was dependent on IL-4 (85). Importantly,
these in vivo findings were complemented by in vitro investigation
of the effects of IL-21 on murine B cells. Thus, IL-21 enhanced pro-
liferation of anti-IgM and/or anti-CD40 mAb-stimulated murine
B cells and initiated PC differentiation and class switching, as
revealed by increased expression of Syndecan-1 (CD138) and
surface IgG1 on these cells (86).
These findings provided strong evidence that IL-21 is likely to
achieve its potent effect on humoral immune responses in vivo
by acting directly on B cells. Indeed, this has been verified in
a series of studies where IL-21R-sufficient or deficient B cells
were adoptively transferred into recipient mice, and the B-cell
response to TD Ags or pathogens then tracked. It was gener-
ally found that when B cells were unable to respond to IL-21,
humoral immunity was compromised with impaired formation of
GC, with respect to magnitude and/or kinetics, and of long-lived
Ag-specific PC. The mechanism underlying aberrant GC forma-
tion was suboptimal induction of Bcl-6 expression in GC B cells,
which attenuated affinity maturation and selection of high-affinity
variants. Although memory cells were generated in normal num-
bers from IL-21R-deficient B cells, the IL-21R-deficient memory
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cells were unable to respond to secondary challenge with specific
Ag, resulting in ineffective recall responses. In contrast to the GC
response, the generation of extrafollicular plasmablasts in response
to pathogens was unaffected by B-cell specific IL-21R-deficiency
(87–92). IL-21 can activate STAT3 (72, 81–84). Intriguingly, analy-
sis of STAT3flox/flox CD19cre mice showed some similarities to mice
whose B cells lacked IL-21R. Specifically, STAT3flox/flox CD19cre
mice have normal levels of serum IgM, IgA, and IgG, but a large
reduction in Ag-specific serum IgG1 levels and splenic PCs fol-
lowing immunization with TD Ags (93). This established that
expression of STAT3 in B cells is important for TD differentiation
of B cells into IgG1-secreting PC (93), with subsequent stud-
ies implicating IL-21 as being the key STAT3-activating cytokine
potentially involved in this process (87–92). Thus, IL-21/IL-21R
signaling, possibly via STAT3, in B cells appears to be required for
the generation and maintenance of long-lived PC and humoral
memory to TD Ags, but is dispensable for GC-independent Ab
responses.
Given the importance of IL-21R expression for normal Ig pro-
duction in vivo (85, 86), a surprising finding was that murine
IL-21 could inhibit B-cell proliferation induced by either anti-
IgM and IL-4, or TLR ligands such as LPS or CpG (94, 95).
Furthermore, although IL-21 impressively promoted proliferation
of CD40-activated B cells, the proportion of B cells that was apop-
totic in the presence of IL-21 exceeded that observed in its absence
(95). Induction of apoptosis by IL-21 in both resting and activated
murine B cells correlated with reduced expression of Bcl-xL and
Bcl-2 and elevated expression of Bim (94, 95). Consistent with this,
IL-21-induced apoptosis could be prevented by restoring expres-
sion of Bcl-xL or Bcl-2 either by overexpressing these proteins or
inducing their expression by activation prior to exposure to IL-21
(94). Increased B-cell apoptosis was also observed in vivo in mice
either transgenic for IL-21 or that received IL-21 administered via
hydrodynamic-based delivery of plasmid DNA. Thus, it appears
that IL-21 can differential influence B-cell fate depending on the
signaling context (86).
Together, these data show that IL-21 is an important factor
for the activation, proliferation, differentiation, Ag production,
or death of murine B cells, with the outcome being dependent
on the context of co-stimulation. The defect in GC-dependent
Ab production in IL-21/IL-21R deficient mice after immunization
indicates that differentiation into PCs may be a non-redundant
activity of IL-21.
IL-21 AND HUMAN B CELLS
Initial studies into the stimulatory effect of IL-21 revealed that
IL-21 potently enhanced the proliferation of CD40-stimulated
human B cells, with memory B cells undergoing a much stronger
proliferative response than naïve B cells (Figure 3; Table 1) (96).
Despite memory B cells proliferating more than naïve B cells in
response to IL-21, the overall effect of IL-21 appeared to be greater
on naïve than on memory cells. Thus, naïve B cells stimulated with
CD40L/IL-21 exhibited a greater enhancement in their response,
as well as a greater reduction in their time to enter cell division,
over that induced by CD40L alone than did memory B cells (76).
This is probably due to the basal expression of IL-21R on naïve B
cells, whereas it is absent from memory cells (Figure 1). Although
expression of IL-21R increases following activation on naïve and
memory B cells, it remained higher on the naive subset (76).
In terms of differentiation, when total CD19+ splenic B cells
were stimulated in vitro with anti-CD40 mAb in the presence
of IL-21, they were induced to secrete IgM and IgG in an IL-21
dose-dependent manner (96). Pene et al. also made the important
observation that IL-21 specifically induced production of IgG1 and
IgG3 by human naïve B cells, demonstrating IL-21 to be a switch
factor for these IgG subclasses (96). The findings from this elegant
study were confirmed by several groups who also found that IL-21
induced proliferation as well as expression and secretion of IgM,
IgG (predominantly IgG3) as well as IgA (mostly IgA1), and IgE
by CD40L-stimulated naïve B cells that had been isolated from
distinct anatomical sites, including umbilical cord blood, spleen,
tonsils, and adult peripheral blood (Figure 3) (60, 76, 97–100)
(Table 1). IL-21 also strongly induced Ig secretion from memory
and GC B cells isolated from these sites (60, 97, 98, 100). The abil-
ity of IL-21 to induce such impressive Ig secretion correlated with
the appearance of a substantial proportion of PCs – phenotypi-
cally identified as CD19loIgD−CD38hi or CD20loCD38hiCD27hi
cells – in cultures of IL-21-stimulated B cells (Figure 3) (60, 98).
Interestingly, a recent report also found IL-21 could support the
survival of and Ig secretion by PCs in secondary lymphoid organs,
but not those in the bone marrow (101). This is consistent with the
differential expression of IL-21R on PCs from these diverse sites
(76, 98, 102) (Figure 1), and suggests that IL-21 contributes to
humoral immunity not only by inducing PC from naïve, memory,
and GC B cells, but also promoting the survival and function of
these cells in lymphoid tissues before they alter their requirements
for survival within niches in bone marrow (67). The ability of IL-
21 to sustain survival of normal PCs is reminiscent of the finding
that IL-21 can promote growth and survival of malignant PC in
multiple myeloma (103).
When compared to other cytokines that have been character-
ized as B-cell growth and differentiation factors, the effect of IL-21
was found to exceed that of IL-2, IL-4, IL-13, and IL-10 by up to
100-fold (60, 76, 97, 98). However, the actions of IL-21 could be
complemented by these cytokines (Table 1; Figure 3). For example,
IL-4 increased the frequency of IgG+ cells generated from, and the
amount of IgG secreted by, naïve B-cell precursors that had been
stimulated with IL-21 (Figure 3) (96, 97). Interestingly, while IL-
21 favored the induction of IgG3+ B cells, the combination of IL-4
and IL-21 resulted in the preferential generation of IgG1+ switched
B cells, which mirrored the effect of IL-4 alone but the magnitude
of the response was greater. IL-4 and IL-21 were also capable of
acting synergistically to induce 10- to 100-fold higher levels of IgE
by CD40L-stimulated naïve B cells over that observed with either
cytokine alone (Figure 3) (96, 99). In contrast, IL-4 abolished not
only IL-21-induced IgM secretion but also switching to and secre-
tion of IgA (97, 98); on the other hand, IgA secretion induced by
IL-21 was augmented by IL-10 (97). Lastly, IL-2 could enhance
PC differentiation induced by IL-21 (Figure 3) (98, 104). This was
achieved by IL-21 inducing expression of CD25 – a component of
the IL-2R – on activated B cells (104).
The physiological significance of these effects of IL-21 on
human B cells has been born from experiments that assessed the
relative contribution(s) of CD4+ T cell-derived cytokines to TD
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FIGURE 3 | Effects of IL-21 on human naïve B cells in vitro. When human
naïve B cells are stimulated with CD40L together with IL-21, they were
found to undergo intense proliferation. This was followed by induction of Ig
class switching – predominantly to IgG3 and IgG1; a lesser extent to
IgA1 – as determined by acquisition of expression of switched isotypes or
differentiation to plasma-like cells capable of secreting all major Ig isotypes.
The B cells that had undergone switching to become IgG+ or IgA+ were
distinct from those that committed to a plasma cell fate – thus, the secreted
Ig detected in these cultures was derived from the in vitro-derived plasma
cells rather than the surface IgG+/IgA+ class switched cells. Both class
switching and plasma cell formation induced by IL-21 could be modulated by
additional cytokines, such as IL-4 (promoted switching to IgG; inhibited
switching to IgA; increased secretion of IgG and IgE; suppressed secretion
of IgM, IgA), IL-10 (increased IgA secretion), and IL-2 (increased secretion of
IgM, IgG). These differentiation events coincided with the induction in
expression of BCL-6, AICDA (required for class switching), and
BLIMP-1/XBP-1 (required for plasma cell formation). The ability of IL-21 to
induce naïve B cells to differentiate into plasmablasts/plasma cells in vitro
was abolished by hypomorphic mutations in STAT3, as well as null
mutations in IL21R or IL2RG.
B-cell differentiation in vitro. Using an in vitro system whereby
human activated CD4+ T cells can induce Ig production by co-
cultured B cells (105), several groups have established that neu-
tralization of IL-21 significantly inhibited T cell-induced B-cell
activation, proliferation, differentiation, Ig secretion, and PC sur-
vival (60, 101, 106). Delayed blockade of IL-21 also inhibited PC
differentiation after initial B-cell expansion, indicating that IL-21
is required for B-cell proliferation and PC differentiation (106).
The findings that IL-21 is highly expressed by Tfh cells (78), and
the IL-21R is upregulated on GC B cells (76) is consistent with
a model of Tfh cells interacting with GC B cells to induce their
differentiation to memory cells and PC predominantly via the
production and delivery of IL-21 (4–6).
MECHANISM OF ACTION OF IL-21
The ability of IL-21 to guide multiple fates in activated B cells –
class switching to express downstream Ig isotypes, commitment to
the PC lineage, as well as formation of GCs and memory B cells –
reflects the ability of IL-21 to induce the molecular machinery
required for these processes. Thus, IL-21 is capable of inducing
expression of AICDA, BLIMP1/PRDM1, and XBP-1, as well as
reducing expression of PAX5, in both human and murine B cells
(Figure 3) (60, 83, 84, 86, 98). Collectively, these factors regulate
class switching and PC formation (8). Interestingly, the ability of
IL-4 to suppress the stimulatory effects of IL-21 on naïve B cells
correlated with a reduction in BLIMP-1 expression (60). IL-21
could also induce BCL-6 (83, 86, 89, 92, 98), which would con-
tribute to GC formation in vivo (Figure 3) (8). Thus, in the setting
of TD B-cell activation, Tfh-derived IL-21 can induce B cells to
express all of the machinery required to undergo the major fates
of differentiation: GC B cells by induction of Bcl-6; PCs follow-
ing induction of BLIMP-1, and class switched B cells by inducing
AICDA. It is likely that IL-21 induces expression of these opposing
transcriptional regulators (i.e., BLIMP-1, Bcl-6) in distinct subsets
of B cells that will ultimately develop into either PC or memory
B cells. However, these outputs will ultimately reflect the balance
of signals received and integrated by the B cells, with the effect of
IL-21 being influenced by inputs delivered via receptors includ-
ing the BCR, other complimentary cytokine, and co-stimulatory
receptors.
As IL-21 can activate several STATs (73), the relative contri-
bution of individual STAT molecules has been assessed. Diehl
et al. demonstrated that constitutive activation of STAT3 in
primary human B cells induced BLIMP-1 expression and ini-
tiated B cell differentiation, yielding cells with a phenotype
(CD38highCD20−CD19lowHLA-DRlowCD138+) consistent with
PC as well as enhanced Ab-secretion (84). Importantly, up-
regulation of BLIMP-1 alone was not sufficient for differentiation
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of primary human B cells into PCs; this event also required con-
comitant down-regulation of BCL-6 (84). This study was the first
to propose that STAT3 was the predominant mediator of the dif-
ferentiation effects that IL-21 has on human B cells. These were
largely confirmed by the demonstration that induction of PRDM1,
XBP-1, and BCL-6 by IL-21 were abolished in naïve B cells isolated
from individuals with hypomorphic mutations in STAT3, while
these responses were unaffected by loss-of-function mutations in
STAT1 (83, 107). Intriguingly, IL-21-induced expression of AICDA
in naïve B cells, as well as of PRDM1 and XBP1 in memory B
cells, still occurred despite the presence of hypomorphic STAT3
mutations, suggesting that class switching in naïve B cells and PC
differentiation from memory B cells requires less STAT3 function
than does the generation of PC from naïve B cells (83, 107).
Interestingly, high-affinity signaling through the BCR on
immortalized B-cell lines can activate STAT3 (108). Similarly,
CD40L enhanced the expression of BLIMP-1 induced by IL-
21/STAT3 signaling in a GC B cell-like human cell line, thereby
maximizing PC differentiation (109). Thus, it is possible that sig-
nals integrated in B cells through receptors such as CD40 and the
BCR can amplify the effects of IL-21 by modulating activating or
function of STAT3. It is also worth noting that STAT3 activation
is important for the survival of multiple myeloma cells (110). As
IL-21 is also anti-apoptotic for myeloma cells, it is tempting to
speculate that IL-21 could contribute to STAT3 activation in vivo
in the setting of this malignancy. Collectively, these studies have
illuminated the pivotal role of IL-21-mediated STAT3 signaling in
guiding key events of human B-cell differentiation.
LESSONS FROM PRIMARY IMMUNODEFICIENCIES
Primary immunodeficiencies (PIDs) result from monogenic
mutations that compromise the ability of affected individuals to
elicit appropriate immune responses. Consequently, these indi-
viduals exhibit susceptibility to infectious diseases and are often
unable to respond to vaccination. As the genetic lesion is known
in many PIDs, these conditions can reveal the unique functions
of specific genes and related signaling pathways in immune cells
and the importance of these pathways in productive and protec-
tive immune responses. Thus, analysis of PIDs can shed new light
on the requirements for lymphocyte development and function.
Indeed, several PIDs have confirmed the critical role played by
IL-21 in humoral immunity in humans.
Heterozygous mutations in STAT3 are the major cause of auto-
somal dominant hyper-IgE syndrome (AD-HIES) (111, 112), a
multisystem disease affecting the immune and musculoskeletal
systems (113, 114). Immunological defects include skin lesions,
recurrent mucocutaneous invasive infections with S. aureus and
Candida. These patients have normal serum levels of IgM, IgG, and
IgA but increased levels of IgE (113, 114). Although the frequen-
cies of total peripheral blood B cells are not significantly different
between AD-HIES patients and control individuals, STAT3 defi-
ciency impaired the in vivo generation of human memory B cells as
well as the generation of Ag-specific Ab-secreting B cells and high-
affinity serum Abs (Figure 2) (83, 107). This reduced number of
memory B cells is in line with previously reported defective func-
tional Ab responses in AD-HIES patients (115–118). Cytokines
known to be involved in human B cell differentiation are IL-6,
IL-10, and IL-21. Consistent with reduced memory B cells and
poor induction of Ag-specific Ab responses in AD-HIES, naïve B
cells from these patients were unable to respond to the stimula-
tory effects of IL-10 or IL-21 with respect to differentiation into PC
in vitro (Figure 3). STAT3 mutations also compromised the ability
of IL-21 to prime B cells to the stimulatory effects of IL-2, inas-
much that induction of CD25 – and subsequent responsiveness to
IL-2 – was attenuated on IL-21-stimulated STAT3-deficient human
naïve B cells (104). These findings revealed that STAT3 plays a
non-redundant role in generating Ag-specific memory B cells and
Ab-secreting cells in vivo. However, it remained to be determined
which STAT3-activating cytokine was requisite for these effects.
This became clearer by examining patients with mutations in
IL2RG, encoding γc, or JAK3, which associates with γc and delivers
signals downstream of γc-containing cytokine receptors (73), that
cause X-linked severe combined immunodeficiency (X-SCID) or
one type of autosomal recessive (AR) SCID, respectively (73, 119).
These PIDs are fatal unless treated by hematopoietic stem cell
transplant (HSCT) (119).
X-linked severe combined immunodeficiency and JAK3 defi-
ciency are characterized by a lack of T and NK cells but normal or
increased numbers of B cells. However, due to the lack of CD4+
T cell help, B cell responses are impaired (119). While HSCT cor-
rects the humoral defect in ~50% of patients, the remainder still
requires ongoing Ig replacement therapy (120). One of the expla-
nations for this is split chimerism, where donor-derived T cells
successfully engraft in the recipient, but autologous host-derived
B cells persist (120). Thus, despite the presence of functional CD4+
T cells, the IL2G/JAK3 mutant B cells remain unable to respond
to T-cell-derived helper signals, rendering the patient immunod-
eficient with respect to humoral immune responses (119, 120).
We took advantage of this chimeric state to examine the B-cell
compartment of X-SCID and JAK3 deficient patients who had
undergone HSCT (121). Although IL-2RG/JAK3 mutant naïve
B cells responded normally to co-stimulatory signals delivered
through the BCR, TLRs, and receptors for IL-10, IL-13, and even
IL-4 [which can also signal through the IL13R; (73)], these B cells
were completely unresponsive to IL-21. Naïve B cells from these
individuals also failed to differentiate into memory cells in vivo
(Figures 2 and 3). Thus, despite intact responsiveness to a suite of
well-characterized B-cell growth and differentiation factors, the
ability to receive signals through a γc-binding/JAK3-activating
cytokine is a critical and rate-limiting step for the establishment of
humoral immunity in humans (Figure 2) (121). Given the potency
that IL-21 exerts on human B-cell differentiation, it was highly
likely that this was the key γc-binding/JAK3-activating cytokine
involved in human B-cell responses in vivo.
This was confirmed by the recent identification of individuals
with homozygous loss-of-function mutations in IL21R that causes
a novel PID, features of which include occasionally reduced serum
IgG levels, poor Ab responses following vaccination with TD Ags
(122), and a paucity of circulating memory B cells, including those
expressing class switched Ig isotypes (107, 122). Not surprisingly,
IL-21R-deficient naïve B cells exhibited impaired IL-21-induced
proliferation, Ig class switching, and PC differentiation in vitro.
This is consistent with a failure of IL-21 to mediate the acquisition
of expression of AICDA, PRDM1, and XBP1 in these cells, and
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mirrors the humoral immune defects observed in these patients.
The cellular and molecular characterization of these patients has
definitively established the criticality of IL-21 in establishing long-
lived humoral immune responses. Furthermore, the finding that
B cells with mutations in IL2RG, JAK3, or STAT3 phenocopy IL-
21R-deficient B cells, with respect to memory cell formation and
responsiveness to IL-21, demonstrates that signaling downstream
of the IL-21R/γc complex via JAK3 and STAT3 is essential for
the effector function of IL-21 on B-cell differentiation in terms
of generating efficient Ag-specific humoral immune responses
(Figures 2 and 3). However, since serum levels of total IgM, IgG,
and IgA are largely normal in most patients with mutations in
either STAT3 or IL-21R, it is clear that the production of basal
Ig is not dependent on IL-21R/STAT3 signaling. Indeed, as we
have previously proposed (83), this is likely achieved by the inter-
play between ligands that do not signal via STAT3 – these could
include many of the cytokines and factors detailed in this review
(see Table 1), such as IL-4, IL-13, BAFF/APRIL as well as TLR
ligands. Despite the availability of these ligands in STAT3- and
IL-21R-deficient patients, and their ability to signal normally in IL-
21R/STAT3-deficient B cells, these factors are collectively unable
to compensate for impaired IL-21R signaling in order to generate
a robust, long lasting Ag-specific Ab response.
Intriguingly, IL-21R-deficient individuals also have elevated
levels of serum IgE (122), which is obviously also a feature of
AD-HIES (113, 114, 116). Thus, it is likely that IL-21 also plays
an important role in regulating IgE production by human B cells.
However, whether this is due to a direct effect of IL-21 on B cells,
or operates through an intermediate cell type [e.g., by inducing
production of IFNγ by T cells and NK cells; (40, 100)] remains to
be determined.
Lastly, it is worth commenting that prior to the discovery
and subsequent characterization of IL-21, IL-10 was considered
to be the most efficient cytokine capable of activating human B
cells (31, 42, 48, 59). As IL-10 can also activate STAT3 (73), and
STAT3-deficient human naïve B cells are unable to respond to the
PC-inducing effects of IL-10 (83), it is possible that the humoral
defects in AD-HIES patients reflects an inability to respond to
not only IL-21 but also IL-10. However, since individuals with
mutations in IL-10 or IL-10R have intact specific Ab responses
to vaccines (123), it is possible the IL-10 plays only a minor role
in regulating human B-cell function in vivo. There are caveats to
this conclusion, however, as most patients examined were young
(<10 years old), and they also suffered from early onset inflam-
matory bowel disease (123). Thus, it remains plausible that IL-10
does contribute to B-cell function in healthy adults.
IL-21/IL-21R AND SYSTEMIC AUTOIMMUNE DISEASES
Just as impaired signaling via IL-21 manifests as humoral immun-
odeficiency, aberrant or excessive IL-21-induced B-cell activa-
tion has been associated with the development of Ab-mediated
autoimmune states in both murine models and human.
The first indication of a potential involvement of IL-21 in
autoimmunity was the finding that IL-21 was overexpressed in
several strains of mice (e.g., BXSB-Yaa, B6.Sle1-Yaa, Sanroque,
MRL/MpJ-FASlpr/lpr/J) that develop lupus-like disease (86, 124,
125). Furthermore, in vivo blockade of IL-21 ameliorated disease
progression and severity in some of these settings (126–128), as
well as in animal models of rheumatoid arthritis (129) and Sjo-
gren’s syndrome (130). This was followed by the demonstration of
elevated expression and/or production of IL-21 in human autoim-
mune conditions including SLE (131–134), rheumatoid arthritis
(135), and Sjogren’s syndrome (136). Consistent with these find-
ings, as well as with the recognition that IL-21 is predominantly
produced by Tfh cells, it was perhaps not surprising that circulating
Tfh-like cells have been detected in a broad array of autoim-
mune conditions including not only SLE, rheumatoid arthritis,
and Sjogren’s syndrome, but also multiple sclerosis, autoimmune
thyroid disease, myasthenia gravis, and juvenile dermatomyosi-
tis [reviewed in Ref. (6, 137)]. Importantly, the increases in Tfh
cells generally correlated with numerous indices of disease sever-
ity, such as titers of autoAb, numbers of Ab-secreting plasmablasts,
clinical scores, and even levels of serum IL-21. Furthermore, the
expanded population of Tfh cells, as well as clinical features
of each of these diseases, could be reduced following initiation
and continuation of immunosuppressive treatments [reviewed
in Ref. (6, 137)]. Independent confirmation that IL-21/IL-21R
may be involved in the development of autoimmune diseases
came from genome-wide association studies. Specifically, poly-
morphisms in either IL-21 or IL-21R genes have been identified
that associated with SLE, RA, and primary Sjogren’s syndrome
(138–141). Collectively, there is convincing evidence that IL-
21 – most likely produced by Tfh cells – plays a pathological
role in the initiation, development, and/or progression of sev-
eral human autoimmune diseases caused by the production of
autoantibodies.
CONCLUDING COMMENTS AND FUTURE PERSPECTIVES
B cells play myriad fundamental roles in providing protective
immunity against infection. However, the most prominent of
these is the production of Ag-specific Ab following the termi-
nal differentiation of B cells into long-lived PCs. This event is
key to the establishment of long-term humoral immunity and
memory, and underlies the success of most currently available
vaccines. The criticality of Ab production by B cells to human
health is evidenced by the pathological consequences of hypogam-
maglobulinemia, resulting in immunodeficiency. Conversely, the
dysregulated production of excessive quantities of self-reactive Abs
can be deleterious in the setting of autoimmunity. The detailed
characterization of the effects of cytokines on B cells – from stud-
ies in genetically manipulated mice, in vitro cultures of human and
murine B cells, and analysis of humans with specific PIDs – have
revealed the central role that IL-21 has in generating memory B
cells and specific Abs following exposure to TD Ags. Remarkably,
alternative signals that could be integrated in B cells through other
cytokine or co-stimulatory receptors are insufficient to initiate
such B-cell responses when the IL-21/IL-21R signaling pathway
is compromised. This paves the way for developing directed ther-
apies to improve immune responses to vaccines or in immuno-
compromised individuals. Supporting this concept is the finding
that administration of IL-21 to macaques increased frequencies
of memory B cells as well as titers of virus-specific IgG (142).
Conversely, therapies aimed at blocking the action of IL-21, either
by directly targeting IL-21 itself or indirectly targeting Tfh cells
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or appropriate signaling molecules downstream of the IL-21R,
so as to restrain the differentiation of rogue, autoreactive B cells
into PCs, represents a feasible strategy for the treatment of var-
ious autoimmune diseases, as evidenced from numerous murine
models (126–129, 143). Hopefully these findings will see success-
ful translation to the clinic, thereby offering new hope for the
treatment of these immune dyscrasias.
ACKNOWLEDGMENTS
The Tangye lab is supported by research grants and fellowships
awarded by the National Health and Medical Research Council of
Australia.
REFERENCES
1. Fagraeus A. The plasma cellular reaction and its relation to the formation of
antibodies in vitro. J Immunol (1948) 58:1–13.
2. Tangye SG, Tarlinton DM. Memory B cells: effectors of long-lived immune
responses. Eur J Immunol (2009) 39:2065–75. doi:10.1002/eji.200939531
3. Goodnow CC, Vinuesa CG, Randall KL, Mackay F, Brink R. Control systems
and decision making for antibody production. Nat Immunol (2010) 11:681–8.
doi:10.1038/ni.1900
4. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol (2011)
29:621–63. doi:10.1146/annurev-immunol-031210-101400
5. Ma CS, Deenick EK, Batten M, Tangye SG. The origins, function, and regula-
tion of T follicular helper cells. J Exp Med (2012) 209:1241–53. doi:10.1084/
jem.20120994
6. Tangye SG, Ma CS, Brink R, Deenick EK. The good, the bad and the ugly –
TFH cells in human health and disease. Nat Rev Immunol (2013) 13:412–26.
doi:10.1038/nri3447
7. Oracki SA, Walker JA, Hibbs ML, Corcoran LM, Tarlinton DM. Plasma cell
development and survival. Immunol Rev (2010) 237:140–59. doi:10.1111/j.
1600-065X.2010.00940.x
8. Nutt SL, Taubenheim N, Hasbold J, Corcoran LM, Hodgkin PD. The
genetic network controlling plasma cell differentiation. Semin Immunol (2011)
23:341–9. doi:10.1016/j.smim.2011.08.010
9. Cattoretti G, Chang CC, Cechova K, Zhang J, Ye BH, Falini B, et al. BCL-6
protein is expressed in germinal-center B cells. Blood (1995) 86:45–53.
10. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation,
cytokine expression, and germinal center formation by BCL-6. Science (1997)
276:589–92. doi:10.1126/science.276.5312.589
11. Fukuda T, Yoshida T, Okada S, Hatano M, Miki T, Ishibashi K, et al. Disruption
of the Bcl6 gene results in an impaired germinal center formation. J Exp Med
(1997) 186:439–48. doi:10.1084/jem.186.3.439
12. Angelin-Duclos C, Cattoretti G, Lin KI, Calame K. Commitment of B lym-
phocytes to a plasma cell fate is associated with Blimp-1 expression in vivo.
J Immunol (2000) 165:5462–71.
13. Kallies A, Hasbold J, Tarlinton DM, Dietrich W, Corcoran LM, Hodgkin PD,
et al. Plasma cell ontogeny defined by quantitative changes in blimp-1 expres-
sion. J Exp Med (2004) 200:967–77. doi:10.1084/jem.20040973
14. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, et al. Blimp-1
orchestrates plasma cell differentiation by extinguishing the mature B cell gene
expression program. Immunity (2002) 17:51–62. doi:10.1016/S1074-7613(02)
00335-7
15. Turner CA Jr, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing
protein that can drive the maturation of B lymphocytes into immunoglobulin-
secreting cells. Cell (1994) 77:297–306. doi:10.1016/0092-8674(94)90321-2
16. Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H, et al.
XBP1, downstream of Blimp-1, expands the secretory apparatus and other
organelles, and increases protein synthesis in plasma cell differentiation. Immu-
nity (2004) 21:81–93. doi:10.1016/j.immuni.2004.06.010
17. Feldmann M, Basten A. Cell interactions in the immune response in vitro. 3.
Specific collaboration across a cell impermeable membrane. J Exp Med (1972)
136:49–67. doi:10.1084/jem.136.4.737
18. Feldmann M, Basten A. Specific collaboration between T and B lymphocytes
across a cell impermeable membrane in vitro. Nat New Biol (1972) 237:13–5.
doi:10.1038/newbio237013a0
19. Gorczynski RM, Miller RG, Phillips RA. Initiation of antibody production to
sheep erythrocytes in vitro: replacement of the requirement for T-cells with
a cell-free factor isolated from cultures of lymphoid cells. J Immunol (1972)
108:547–51.
20. Taussig J, Mozes E, Isac R. Antigen-specific thymus cell factors in the genetic
control of the immune response to poly-(tyrosyl, glutamyl)-poly-D, L-alanyl –
poly-lysyl. J Exp Med (1974) 140:301–12.
21. Kuhara T, Haughton G, Corley RB. Antigen-nonspecific T cell-derived fac-
tors in B cell activation: differences in the requirements for interleukin 2 in
responses of unprimed and primed B cells. Eur J Immunol (1985) 15:787–93.
doi:10.1002/eji.1830150809
22. Jelinek DF, Lipsky PE. The roles of T cell factors in activation, cell cycle progres-
sion, and differentiation of human B cells. J Immunol (1985) 134:1690–701.
23. Kishimoto T. Factors affecting B-cell growth and differentiation. Annu Rev
Immunol (1985) 3:133–57. doi:10.1146/annurev.iy.03.040185.001025
24. Armitage RJ, Macduff BM, Eisenman J, Paxton R, Grabstein KH. IL-15 has
stimulatory activity for the induction of B cell proliferation and differentiation.
J Immunol (1995) 154:483–90.
25. Armitage RJ, Macduff BM, Spriggs MK, Fanslow WC. Human B cell prolifera-
tion and Ig secretion induced by recombinant CD40 ligand are modulated by
soluble cytokines. J Immunol (1993) 150:3671–80.
26. Arpin C, Dechanet J, Van Kooten C, Merville P, Grouard G, Briere F, et al. Gen-
eration of memory B cells and plasma cells in vitro. Science (1995) 268:720–2.
doi:10.1126/science.7537388
27. Aversa G, Punnonen J, de Vries JE. The 26-kD transmembrane form of tumor
necrosis factor alpha on activated CD4+ T cell clones provides a costimu-
latory signal for human B cell activation. J Exp Med (1993) 177:1575–85.
doi:10.1084/jem.177.6.1575
28. Cocks BG, de Waal Malefyt R, Galizzi JP, de Vries JE, Aversa G. IL-13 induces
proliferation and differentiation of human B cells activated by the CD40 ligand.
Int Immunol (1993) 5:657–63. doi:10.1093/intimm/5.6.657
29. McKenzie AN, Culpepper JA, de Waal Malefyt R, Briere F, Punnonen J,
Aversa G, et al. Interleukin 13, a T-cell-derived cytokine that regulates human
monocyte and B-cell function. Proc Natl Acad Sci U S A (1993) 90:3735–9.
doi:10.1073/pnas.90.8.3735
30. Delfraissy JF, Wallon C, Galanaud P. Interferon-alpha can synergize with
interleukin 2 for human in vitro antibody response. Eur J Immunol (1988)
18:1379–84. doi:10.1002/eji.1830180912
31. Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J. Inter-
leukin 10 and transforming growth factor beta cooperate to induce anti-CD40-
activated naive human B cells to secrete immunoglobulin A. J Exp Med (1992)
175:671–82. doi:10.1084/jem.175.3.671
32. Dubois B, Massacrier C, Vanbervliet B, Fayette J, Briere F, Banchereau J, et al.
Critical role of IL-12 in dendritic cell-induced differentiation of naive B lym-
phocytes. J Immunol (1998) 161:2223–31.
33. Gauchat JF, Aversa G, Gascan H, de Vries JE. Modulation of IL-4 induced
germline epsilon RNA synthesis in human B cells by tumor necrosis factor-
alpha, anti-CD40 monoclonal antibodies or transforming growth factor-beta
correlates with levels of IgE production. Int Immunol (1992) 4:397–406.
34. Itoh K, Hirohata S. The role of IL-10 in human B cell activation, proliferation,
and differentiation. J Immunol (1995) 154:4341–50.
35. Jelinek DF, Lipsky PE. Inhibitory influence of IL-4 on human B cell respon-
siveness. J Immunol (1988) 141:164–73.
36. Kehrl JH, Muraguchi A, Fauci AS. The effects of interleukin-1, interleukin-2,
alpha-interferon, and gamma-interferon on human B lymphocytes. Trans Assoc
Am Physicians (1984) 97:182–9.
37. Lundgren M, Persson U, Larsson P, Magnusson C, Smith CI, Hammarstrom
L, et al. Interleukin 4 induces synthesis of IgE and IgG4 in human B cells.
Eur J Immunol (1989) 19:1311–5. doi:10.1002/eji.1830190724
38. Mingari MC, Gerosa F, Carra G, Accolla RS, Moretta A, Zubler RH, et al.
Human interleukin-2 promotes proliferation of activated B cells via sur-
face receptors similar to those of activated T cells. Nature (1984) 312:641–3.
doi:10.1038/312641a0
39. Nakagawa T, Hirano T, Nakagawa N,Yoshizaki K, Kishimoto T. Effect of recom-
binant IL 2 and gamma-IFN on proliferation and differentiation of human B
cells. J Immunol (1985) 134:959–66.
40. Pene J, Rousset F, Briere F, Chretien I, Bonnefoy JY, Spits H, et al. IgE produc-
tion by normal human lymphocytes is induced by interleukin 4 and suppressed
Frontiers in Immunology | B Cell Biology February 2014 | Volume 5 | Article 65 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Moens and Tangye Cytokines and plasma cells
by interferons gamma and alpha and prostaglandin E2. Proc Natl Acad Sci U S
A (1988) 85:6880–4. doi:10.1073/pnas.85.18.6880
41. Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G, et al.
Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and
CD23 expression by human B cells. Proc Natl Acad Sci U S A (1993) 90:3730–4.
doi:10.1073/pnas.90.8.3730
42. Rousset F, Garcia E, Defrance T, Peronne C,Vezzio N, Hsu DH, et al. Interleukin
10 is a potent growth and differentiation factor for activated human B lympho-
cytes. Proc Natl Acad Sci U S A (1992) 89:1890–3. doi:10.1073/pnas.89.5.1890
43. Splawski JB, Jelinek DF, Lipsky PE. Immunomodulatory role of IL-4 on the
secretion of Ig by human B cells. J Immunol (1989) 142:1569–75.
44. Splawski JB, McAnally LM, Lipsky PE. IL-2 dependence of the promotion
of human B cell differentiation by IL-6 (BSF-2). J Immunol (1990) 144:
562–9.
45. Vercelli D, Jabara HH, Arai K, Yokota T, Geha RS. Endogenous interleukin
6 plays an obligatory role in interleukin 4-dependent human IgE synthesis.
Eur J Immunol (1989) 19:1419–24. doi:10.1002/eji.1830190811
46. Vernino L, McAnally LM, Ramberg J, Lipsky PE. Generation of nondividing
high rate Ig-secreting plasma cells in cultures of human B cells stimulated with
anti-CD3-activated T cells. J Immunol (1992) 148:404–10.
47. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacy-
toid dendritic cells induce plasma cell differentiation through type I interferon
and interleukin 6. Immunity (2003) 19:225–34. doi:10.1016/S1074-7613(03)
00208-5
48. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C,
et al. The CD40 antigen and its ligand. Annu Rev Immunol (1994) 12:
881–922.
49. Aversa G, Punnonen J, Cocks BG, de Waal Malefyt R, Vega F Jr, Zurawski
SM, et al. An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-
13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell
proliferation: support for a common component shared by IL-4 and IL-13
receptors. J Exp Med (1993) 178:2213–8. doi:10.1084/jem.178.6.2213
50. Defrance T, Carayon P, Billian G, Guillemot JC, Minty A, Caput D, et al.
Interleukin 13 is a B cell stimulating factor. J Exp Med (1994) 179:135–43.
doi:10.1084/jem.179.1.135
51. Maliszewski CR, Grabstein K, Fanslow WC, Armitage R, Spriggs MK, Sato TA.
Recombinant CD40 ligand stimulation of murine B cell growth and differ-
entiation: cooperative effects of cytokines. Eur J Immunol (1993) 23:1044–9.
doi:10.1002/eji.1830230510
52. Kuhn R, Rajewsky K, Muller W. Generation and analysis of interleukin-4 defi-
cient mice. Science (1991) 254:707–10.
53. Kimata H, Yoshida A, Ishioka C, Lindley I, Mikawa H. Interleukin 8 (IL-8)
selectively inhibits immunoglobulin E production induced by IL-4 in human
B cells. J Exp Med (1992) 176:1227–31. doi:10.1084/jem.176.4.1227
54. Kiniwa M, Gately M, Gubler U, Chizzonite R, Fargeas C, Delespesse G.
Recombinant interleukin-12 suppresses the synthesis of immunoglobulin E by
interleukin-4 stimulated human lymphocytes. J Clin Invest (1992) 90:262–6.
doi:10.1172/JCI115846
55. Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts
on monocytes and B cells, but not on T cells. Immunol Today (1994) 15:19–26.
56. Lai YH, Mosmann TR. Mouse IL-13 enhances antibody production in vivo
and acts directly on B cells in vitro to increase survival and hence antibody
production. J Immunol (1999) 162:78–87.
57. Emson CL, Bell SE, Jones A, Wisden W, McKenzie AN. Interleukin (IL)-
4-independent induction of immunoglobulin (Ig)E, and perturbation of T
cell development in transgenic mice expressing IL-13. J Exp Med (1998)
188:399–404. doi:10.1084/jem.188.2.399
58. McKenzie GJ, Fallon PG, Emson CL, Grencis RK, McKenzie AN. Simulta-
neous disruption of interleukin (IL)-4 and IL-13 defines individual roles in
T helper cell type 2-mediated responses. J Exp Med (1999) 189:1565–72.
doi:10.1084/jem.189.10.1565
59. Briere F, Servet-Delprat C, Bridon JM, Saint-Remy JM, Banchereau J. Human
interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells
to secrete IgG1 and IgG3. J Exp Med (1994) 179:757–62. doi:10.1084/jem.179.
2.757
60. Bryant VL, Ma CS, Avery DT, Li Y, Good KL, Corcoran LM, et al. Cytokine-
mediated regulation of human B cell differentiation into Ig-secreting cells:
predominant role of IL-21 produced by CXCR5+ T follicular helper cells.
J Immunol (2007) 179:8180–90.
61. Groux H, Cottrez F, Rouleau M, Mauze S, Antonenko S, Hurst S, et al. A trans-
genic model to analyze the immunoregulatory role of IL-10 secreted by antigen-
presenting cells. J Immunol (1999) 162:1723–9.
62. Hagenbaugh A, Sharma S, Dubinett SM, Wei SH, Aranda R, Cheroutre H, et al.
Altered immune responses in interleukin 10 transgenic mice. J Exp Med (1997)
185:2101–10. doi:10.1084/jem.185.12.2101
63. Macchia D, Almerigogna F, Parronchi P, Ravina A, Maggi E, Romagnani S.
Membrane tumour necrosis factor-alpha is involved in the polyclonal B-cell
activation induced by HIV-infected human T cells. Nature (1993) 363:464–6.
doi:10.1038/363464a0
64. Cerutti A, Puga I, Cols M. Innate control of B cell responses. Trends Immunol
(2011) 32:202–11. doi:10.1016/j.it.2011.02.004
65. Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial
on B cell survival. Annu Rev Immunol (2003) 21:231–64. doi:10.1146/annurev.
immunol.21.120601.141152
66. Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell
disorders. Semin Immunol (2006) 18:305–17. doi:10.1016/j.smim.2006.04.004
67. Tangye SG. Staying alive: regulation of plasma cell survival. Trends Immunol
(2011) 32:595–602. doi:10.1016/j.it.2011.09.001
68. Huard B, McKee T, Bosshard C, Durual S, Matthes T, Myit S, et al. APRIL
secreted by neutrophils binds to heparan sulfate proteoglycans to create
plasma cell niches in human mucosa. J Clin Invest (2008) 118:2887–95.
doi:10.1172/JCI33760
69. Reijmers RM, Groen RW, Kuil A, Weijer K, Kimberley FC, Medema JP, et al.
Disruption of heparan sulfate proteoglycan conformation perturbs B-cell mat-
uration and APRIL-mediated plasma cell survival. Blood (2011) 117:6162–71.
doi:10.1182/blood-2010-12-325522
70. Ozaki K, Kikly K, Michalovich D, Young PR, Leonard WJ. Cloning of a type I
cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad
Sci U S A (2000) 97:11439–44. doi:10.1073/pnas.200360997
71. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, et al.
Interleukin 21 and its receptor are involved in NK cell expansion and regulation
of lymphocyte function. Nature (2000) 408:57–63. doi:10.1038/35040504
72. Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, Foster D, et al. Cutting edge:
the common gamma-chain is an indispensable subunit of the IL-21 receptor
complex. J Immunol (2001) 167:1–5.
73. Leonard WJ. Cytokines and immunodeficiency diseases. Nat Rev Immunol
(2001) 1:200–8. doi:10.1038/35105066
74. Caruso R, Fina D, Peluso I, Stolfi C, Fantini MC, Gioia V, et al. A functional
role for interleukin-21 in promoting the synthesis of the T-cell chemoattrac-
tant, MIP-3alpha, by gut epithelial cells. Gastroenterology (2007) 132:166–75.
doi:10.1053/j.gastro.2006.09.053
75. Distler JH, Jungel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott H, et al.
Expression of interleukin-21 receptor in epidermis from patients with systemic
sclerosis. Arthritis Rheum (2005) 52:856–64. doi:10.1002/art.20883
76. Good KL, Bryant VL, Tangye SG. Kinetics of human B cell behavior and ampli-
fication of proliferative responses following stimulation with IL-21. J Immunol
(2006) 177:5236–47.
77. Jungel A, Distler JH, Kurowska-Stolarska M, Seemayer CA, Seibl R, Forster A,
et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial
fibroblasts and synovial macrophages of patients with rheumatoid arthritis.
Arthritis Rheum (2004) 50:1468–76. doi:10.1002/art.20218
78. Chtanova T, Tangye SG, Newton R, Frank N, Hodge MR, Rolph MS, et al.
T follicular helper cells express a distinctive transcriptional profile, reflecting
their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol
(2004) 173:68–78.
79. Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, Smyth MJ, et al.
IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine
production. J Immunol (2007) 178:2827–34.
80. Luthje K, Kallies A, Shimohakamada Y, Belz GT, Light A, Tarlinton DM, et al.
The development and fate of follicular helper T cells defined by an IL-21
reporter mouse. Nat Immunol (2012) 13:491–8. doi:10.1038/ni.2261
81. Habib T, Nelson A, Kaushansky K. IL-21: a novel IL-2-family lymphokine that
modulates B, T, and natural killer cell responses. J Allergy Clin Immunol (2003)
112:1033–45. doi:10.1016/j.jaci.2003.08.039
82. Habib T, Senadheera S, Weinberg K, Kaushansky K. The common gamma
chain (gamma c) is a required signaling component of the IL-21 receptor
and supports IL-21-induced cell proliferation via JAK3. Biochemistry (2002)
41:8725–31. doi:10.1021/bi0202023
www.frontiersin.org February 2014 | Volume 5 | Article 65 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Moens and Tangye Cytokines and plasma cells
83. Avery DT, Deenick EK, Ma CS, Suryani S, Simpson N, Chew GY, et al. B cell-
intrinsic signaling through IL-21 receptor and STAT3 is required for establish-
ing long-lived antibody responses in humans. J Exp Med (2010) 207:155–71.
doi:10.1084/jem.20091706
84. Diehl SA, Schmidlin H, Nagasawa M, van Haren SD, Kwakkenbos MJ, Yasuda
E, et al. STAT3-mediated up-regulation of BLIMP1 is coordinated with BCL6
down-regulation to control human plasma cell differentiation. J Immunol
(2008) 180:4805–15.
85. Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, et al. A critical role for
IL-21 in regulating immunoglobulin production. Science (2002) 298:1630–4.
doi:10.1126/science.1077002
86. Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, Qi CF, et al. Regulation of
B cell differentiation and plasma cell generation by IL-21, a novel inducer of
Blimp-1 and Bcl-6. J Immunol (2004) 173:5361–71.
87. Bessa J, Kopf M, Bachmann MF. Cutting edge: IL-21 and TLR signaling regu-
late germinal center responses in a B cell-intrinsic manner. J Immunol (2010)
184:4615–9. doi:10.4049/jimmunol.0903949
88. King IL, Mohrs K, Mohrs M. A nonredundant role for IL-21 receptor signal-
ing in plasma cell differentiation and protective type 2 immunity against gas-
trointestinal helminth infection. J Immunol (2010) 185:6138–45. doi:10.4049/
jimmunol.1001703
89. Linterman MA, Beaton L, Yu D, Ramiscal RR, Srivastava M, Hogan JJ, et al.
IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center
responses. J Exp Med (2010) 207:353–63. doi:10.1084/jem.20091738
90. Rankin AL, MacLeod H, Keegan S, Andreyeva T, Lowe L, Bloom L, et al. IL-21
receptor is critical for the development of memory B cell responses. J Immunol
(2011) 186:667–74. doi:10.4049/jimmunol.0903207
91. Rasheed MA, Latner DR, Aubert RD, Gourley T, Spolski R, Davis CW, et al.
Interleukin-21 is a critical cytokine for the generation of virus-specific long-
lived plasma cells. J Virol (2013) 87:7737–46. doi:10.1128/JVI.00063-13
92. Zotos D, Coquet JM, Zhang Y, Light A, D’Costa K, Kallies A, et al. IL-21 regu-
lates germinal center B cell differentiation and proliferation through a B cell-
intrinsic mechanism. J Exp Med (2010) 207:365–78. doi:10.1084/jem.20091777
93. Fornek JL, Tygrett LT, Waldschmidt TJ, Poli V, Rickert RC, Kansas GS. Criti-
cal role for Stat3 in T-dependent terminal differentiation of IgG B cells. Blood
(2006) 107:1085–91. doi:10.1182/blood-2005-07-2871
94. Mehta DS, Wurster AL, Whitters MJ, Young DA, Collins M, Grusby MJ. IL-
21 induces the apoptosis of resting and activated primary B cells. J Immunol
(2003) 170:4111–8.
95. Jin H, Carrio R, Yu A, Malek TR. Distinct activation signals determine whether
IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis.
J Immunol (2004) 173:657–65.
96. Pene J, Gauchat JF, Lecart S, Drouet E, Guglielmi P, Boulay V, et al. Cutting
edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B
cells. J Immunol (2004) 172:5154–7.
97. Avery DT, Bryant VL, Ma CS, de Waal Malefyt R, Tangye SG. IL-21-induced iso-
type switching to IgG and IgA by human naive B cells is differentially regulated
by IL-4. J Immunol (2008) 181:1767–79.
98. Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, Spolski R, et al. IL-
21 induces differentiation of human naive and memory B cells into antibody-
secreting plasma cells. J Immunol (2005) 175:7867–79.
99. Avery DT, Ma CS, Bryant VL, Santner-Nanan B, Nanan R, Wong M, et al. STAT3
is required for IL-21-induced secretion of IgE from human naive B cells. Blood
(2008) 112:1784–93. doi:10.1182/blood-2008-02-142745
100. Pene J, Guglielmi L, Gauchat JF, Harrer N, Woisetschlager M, Boulay V, et al.
IFN-gamma-mediated inhibition of human IgE synthesis by IL-21 is associated
with a polymorphism in the IL-21R gene. J Immunol (2006) 177:5006–13.
101. Rodriguez-Bayona B, Ramos-Amaya A, Bernal J, Campos-Caro A, Brieva JA.
Cutting edge: IL-21 derived from human follicular helper T cells acts as a sur-
vival factor for secondary lymphoid organ, but not for bone marrow, plasma
cells. J Immunol (2012) 188:1578–81. doi:10.4049/jimmunol.1102786
102. Rodriguez-Bayona B, Ramos-Amaya A, Lopez-Blanco R, Campos-Caro A,
Brieva JA. STAT-3 activation by differential cytokines is critical for human
in vivo-generated plasma cell survival and Ig secretion. J Immunol (2013)
191:4996–5004. doi:10.4049/jimmunol.1301559
103. Brenne AT, Ro TB, Waage A, Sundan A, Borset M, Hjorth-Hansen H.
Interleukin-21 is a growth and survival factor for human myeloma cells. Blood
(2002) 99:3756–62. doi:10.1182/blood.V99.10.3756
104. Berglund LJ, Avery DT, Ma CS, Moens L, Deenick EK, Bustamante J, et al.
IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2
to enhance their differentiation into plasmablasts. Blood (2013) 122:3940–50.
doi:10.1182/blood-2013-06-506865
105. Hirohata S, Jelinek DF, Lipsky PE. T cell-dependent activation of B cell pro-
liferation and differentiation by immobilized monoclonal antibodies to CD3.
J Immunol (1988) 140:3736–44.
106. Kuchen S, Robbins R, Sims GP, Sheng C, Phillips TM, Lipsky PE, et al. Essential
role of IL-21 in B cell activation, expansion, and plasma cell generation during
CD4+ T cell-B cell collaboration. J Immunol (2007) 179:5886–96.
107. Deenick EK, Avery DT, Chan A, Berglund LJ, Ives ML, Moens L, et al. Naive and
memory human B cells have distinct requirements for STAT3 activation to dif-
ferentiate into antibody-secreting plasma cells. J Exp Med (2013) 210:2739–53.
doi:10.1084/jem.20130323
108. Wang L, Kurosaki T, Corey SJ. Engagement of the B-cell antigen receptor
activates STAT through Lyn in a Jak-independent pathway. Oncogene (2007)
26:2851–9. doi:10.1038/sj.onc.1210092
109. Ding BB, Bi E, Chen H, Yu JJ, Ye BH. IL-21 and CD40L synergistically promote
plasma cell differentiation through upregulation of Blimp-1 in human B cells.
J Immunol (2013) 190:1827–36. doi:10.4049/jimmunol.1201678
110. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino
R, et al. Constitutive activation of Stat3 signaling confers resistance to apopto-
sis in human U266 myeloma cells. Immunity (1999) 10:105–15. doi:10.1016/
S1074-7613(00)80011-4
111. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3
mutations in the hyper-IgE syndrome. N Engl J Med (2007) 357:1608–19.
doi:10.1056/NEJMoa073687
112. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, et al. Dominant-
negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE
syndrome. Nature (2007) 448:1058–62. doi:10.1038/nature06096
113. Freeman AF, Holland SM. The hyper-IgE syndromes. Immunol Allergy Clin
North Am (2008) 28:277–291, viii. doi:10.1016/j.iac.2008.01.005
114. Grimbacher B, Holland SM, Puck JM. Hyper-IgE syndromes. Immunol Rev
(2005) 203:244–50. doi:10.1111/j.0105-2896.2005.00228.x
115. Dreskin SC, Goldsmith PK, Gallin JI. Immunoglobulins in the hyperim-
munoglobulin E and recurrent infection (Job’s) syndrome. Deficiency of
anti-Staphylococcus aureus immunoglobulin A. J Clin Invest (1985) 75:26–34.
doi:10.1172/JCI111683
116. Buckley RH, Wray BB, Belmaker EZ. Extreme hyperimmunoglobulinemia E
and undue susceptibility to infection. Pediatrics (1972) 49:59–70.
117. Leung DY,Ambrosino DM,Arbeit RD, Newton JL, Geha RS. Impaired antibody
responses in the hyperimmunoglobulin E syndrome. J Allergy Clin Immunol
(1988) 81:1082–7. doi:10.1016/0091-6749(88)90873-1
118. Sheerin KA, Buckley RH. Antibody responses to protein, polysaccharide,
and phi X174 antigens in the hyperimmunoglobulinemia E (hyper-IgE)
syndrome. J Allergy Clin Immunol (1991) 87:803–11. doi:10.1016/0091-
6749(91)90126-9
119. Buckley RH. Molecular defects in human severe combined immunodefi-
ciency and approaches to immune reconstitution. Annu Rev Immunol (2004)
22:625–55. doi:10.1146/annurev.immunol.22.012703.104614
120. Buckley RH. B-cell function in severe combined immunodeficiency after stem
cell or gene therapy: a review. J Allergy Clin Immunol (2010) 125:790–7.
doi:10.1016/j.jaci.2010.02.012
121. Recher M, Berglund LJ, Avery DT, Cowan MJ, Gennery AR, Smart J, et al. IL-21
is the primary common gamma chain-binding cytokine required for human
B-cell differentiation in vivo. Blood (2011) 118:6824–35. doi:10.1182/blood-
2011-06-362533
122. Kotlarz D, Zietara N, Uzel G, Weidemann T, Braun CJ, Diestelhorst J, et al. Loss-
of-function mutations in the IL-21 receptor gene cause a primary immunode-
ficiency syndrome. J Exp Med (2013) 210:433–43. doi:10.1084/jem.20111229
123. Kotlarz D, Beier R, Murugan D, Diestelhorst J, Jensen O, Boztug K, et al.
Loss of interleukin-10 signaling and infantile inflammatory bowel disease:
implications for diagnosis and therapy. Gastroenterology (2012) 143:347–55.
doi:10.1053/j.gastro.2012.04.045
124. Vinuesa CG, Cook MC, Angelucci C, Athanasopoulos V, Rui L, Hill KM,
et al. A RING-type ubiquitin ligase family member required to repress follic-
ular helper T cells and autoimmunity. Nature (2005) 435:452–8. doi:10.1038/
nature03555
Frontiers in Immunology | B Cell Biology February 2014 | Volume 5 | Article 65 | 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Moens and Tangye Cytokines and plasma cells
125. Subramanian S, Tus K, Li QZ, Wang A, Tian XH, Zhou J, et al. A Tlr7 translo-
cation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci
U S A (2006) 103:9970–5. doi:10.1073/pnas.0603912103
126. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos
K. IL-21 has a pathogenic role in a lupus-prone mouse model and its block-
ade with IL-21R.Fc reduces disease progression. J Immunol (2007) 178:
3822–30.
127. Bubier JA, Sproule TJ, Foreman O, Spolski R, Shaffer DJ, Morse HC III, et al.
A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus
erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A (2009) 106:1518–23.
doi:10.1073/pnas.0807309106
128. Rankin AL, Guay H, Herber D, Bertino SA, Duzanski TA, Carrier Y, et al. IL-21
receptor is required for the systemic accumulation of activated B and T lym-
phocytes in MRL/MpJ-Fas(lpr/lpr)/J mice. J Immunol (2012) 188:1656–67.
doi:10.4049/jimmunol.1003871
129. Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, et al. Blockade
of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in
animal models of rheumatoid arthritis. Arthritis Rheum (2007) 56:1152–63.
doi:10.1002/art.22452
130. Liu H, Liu G, Gong L, Zhang Y, Jiang G. Local suppression of IL-21 in sub-
mandibular glands retards the development of Sjogren’s syndrome in non-
obese diabetic mice. J Oral Pathol Med (2012) 41:728–35. doi:10.1111/j.1600-
0714.2012.01175.x
131. Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW. Elevated production of
B cell chemokine CXCL13 is correlated with systemic lupus erythematosus dis-
ease activity. J Clin Immunol (2010) 30:45–52. doi:10.1007/s10875-009-9325-5
132. Dolff S, Abdulahad WH, Westra J, Doornbos-van der Meer B, Limburg PC,
Kallenberg CG, et al. Increase in IL-21 producing T-cells in patients with sys-
temic lupus erythematosus. Arthritis Res Ther (2011) 13:R157. doi:10.1186/
ar3474
133. Nakou M, Papadimitraki ED, Fanouriakis A, Bertsias GK, Choulaki C, Gouli-
daki N, et al. Interleukin-21 is increased in active systemic lupus erythematosus
patients and contributes to the generation of plasma B cells. Clin Exp Rheumatol
(2013) 31:172–9.
134. Terrier B, Costedoat-Chalumeau N, Garrido M, Geri G, Rosenzwajg M,
Musset L, et al. Interleukin 21 correlates with T cell and B cell subsetal-
terations in systemic lupus erythematosus. J Rheumatol (2012) 39:1819–28.
doi:10.3899/jrheum.120468
135. Ma J, Zhu C, Ma B, Tian J, Baidoo SE, Mao C, et al. Increased frequency of
circulating follicular helper T cells in patients with rheumatoid arthritis. Clin
Dev Immunol (2012) 2012:827480. doi:10.1155/2012/827480
136. Kang KY, Kim HO, Kwok SK, Ju JH, Park KS, Sun DI, et al. Impact of
interleukin-21 in the pathogenesis of primary Sjogren’s syndrome: increased
serum levels of interleukin-21 and its expression in the labial salivary glands.
Arthritis Res Ther (2011) 13:R179. doi:10.1186/ar3504
137. Ma CS, Deenick EK. Human T follicular helper (Tfh) cells and disease. Immunol
Cell Biol (2014) 92:64–71. doi:10.1038/icb.2013.55
138. Sawalha AH, Kaufman KM, Kelly JA, Adler AJ, Aberle T, Kilpatrick J, et al.
Genetic association of interleukin-21 polymorphisms with systemic lupus
erythematosus. Ann Rheum Dis (2008) 67:458–61. doi:10.1136/ard.2007.
075424
139. Webb R, Merrill JT, Kelly JA, Sestak A, Kaufman KM, Langefeld CD, et al.
A polymorphism within IL21R confers risk for systemic lupus erythematosus.
Arthritis Rheum (2009) 60:2402–7. doi:10.1002/art.24658
140. Maiti AK, Kim-Howard X, Viswanathan P, Guillen L, Rojas-Villarraga A, Desh-
mukh H, et al. Confirmation of an association between rs6822844 at the IL2-
IL21 region and multiple autoimmune diseases: evidence of a general suscep-
tibility locus. Arthritis Rheum (2010) 62:323–9. doi:10.1002/art.27222
141. Daha NA, Kurreeman FA, Marques RB, Stoeken-Rijsbergen G, Verduijn W,
Huizinga TW, et al. Confirmation of STAT4, IL2/IL21, and CTLA4 poly-
morphisms in rheumatoid arthritis. Arthritis Rheum (2009) 60:1255–60.
doi:10.1002/art.24503
142. Pallikkuth S, Rogers K, Villinger F, Dosterii M, Vaccari M, Franchini G, et al.
Interleukin-21 administration to rhesus macaques chronically infected with
simian immunodeficiency virus increases cytotoxic effector molecules in T cells
and NK cells and enhances B cell function without increasing immune acti-
vation or viral replication. Vaccine (2011) 29:9229–38. doi:10.1016/j.vaccine.
2011.09.118
143. McPhee CG, Bubier JA, Sproule TJ, Park G, Steinbuck MP, Schott WH, et al. IL-
21 is a double-edged sword in the systemic lupus erythematosus-like disease of
BXSB.Yaa mice. J Immunol (2013) 191:4581–8. doi:10.4049/jimmunol.1300439
144. Itoh K, Inoue T, Ito K, Hirohata S. The interplay of interleukin-10 (IL-10) and
interleukin-2 (IL-2) in humoral immune responses: IL-10 synergizes with IL-2
to enhance responses of human B lymphocytes in a mechanism which is differ-
ent from upregulation of CD25 expression. Cell Immunol (1994) 157:478–88.
doi:10.1006/cimm.1994.1243
145. Le Gallou S, Caron G, Delaloy C, Rossille D, Tarte K, Fest T. IL-2 require-
ment for human plasma cell generation: coupling differentiation and prolif-
eration by enhancing MAPK-ERK signaling. J Immunol (2012) 189:161–73.
doi:10.4049/jimmunol.1200301
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 12 December 2013; accepted: 05 February 2014; published online: 18 February
2014.
Citation: Moens L and Tangye SG (2014) Cytokine-mediated regulation of
plasma cell generation: IL-21 takes center stage. Front. Immunol. 5:65. doi:
10.3389/fimmu.2014.00065
This article was submitted to B Cell Biology, a section of the journal Frontiers in
Immunology.
Copyright © 2014 Moens and Tangye. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
www.frontiersin.org February 2014 | Volume 5 | Article 65 | 13
